uMed’s research & engagement platform secures seed funding from Playfair Capital
- uMed partners with London based Playfair Capital, London’s leading seed-stage investor
- Investment will allow uMed to continue building its global research network
- uMed’s unique model and technology will enable rapid, low cost clinical trials
08th October 2019; uMed, the London based health-technology company has announced it has secured seed investment from Playfair Capital.
uMed’s technology enables healthcare providers to deliver cutting edge research to their patients, with minimal intervention from in-house staff. Through a novel process that combines the richness of electronic health records with targeted patient engagement, uMed securely connects researchers with patients and removes the burden on study sites. uMed is the most powerful solution for researchers to conduct real-time, real-world programmes to power cures in the 21st century.
Dr Matt Wilson, CEO uMed, commented: “It is fantastic to be working with the Playfair Capital team who share our vision of making cutting edge research accessible to all healthcare providers and their patients”
Chris Smith, Partner at Playfair Capital, “We really believe that uMed and the team have the expertise and potential to fundamentally improve peoples’ lives and that patient engagement is the key to unlocking this sector’s potential”